

# Massimo Offidani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8497596/publications.pdf>

Version: 2024-02-01

143  
papers

11,744  
citations

57758

44  
h-index

28297

105  
g-index

144  
all docs

144  
docs citations

144  
times ranked

8890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	2.2	5
2	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. <i>Cells</i> , 2022, 11, 606.	4.1	8
3	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> , 2022, 15, 519-537.	2.2	1
4	Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2021, 100, 429-436.	1.8	17
5	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	4.4	4
6	Novel Experimental Drugs for Treatment of Multiple Myeloma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 245-264.	3.2	16
7	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	6.2	7
8	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
9	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	4.1	4
10	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	1.4	40
11	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2401-2415.	4.3	26
12	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
13	Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 619-629.	2.3	2
14	Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2021, 138, 4871-4871.	1.4	0
15	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1710.	10.7	120
16	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	6.2	5
17	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
18	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16

#	ARTICLE	IF	CITATIONS
19	Introduction to "Immunotherapies for Multiple Myeloma". Pharmaceuticals, 2020, 13, 396.	3.8	4
20	Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. Pharmaceuticals, 2020, 13, 426.	3.8	4
21	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. Blood Cancer Journal, 2020, 10, 58.	6.2	9
22	Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Expert Review of Hematology, 2020, 13, 351-362.	2.2	4
23	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 2020, 106, 291-294.	3.5	17
24	Autologous haematopoietic stem-cell transplantation versus bortezomib "melphalan" prednisone, with or without bortezomib "lenalidomide" dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology, the, 2020, 7, e456-e468.	4.6	244
25	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	6.2	15
26	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	1.4	16
27	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	5.7	35
28	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology and Oncology, 2019, 12, 4.	17.0	27
29	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica, 2019, 104, 1640-1647.	3.5	22
30	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer, 2019, 125, 750-760.	4.1	31
31	"Real-life" analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1062-1068.	3.0	11
32	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
33	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1357-1366.	2.5	8
34	Triplet vs. doublet drug regimens for managing multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 137-149.	1.8	21
35	A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. Future Oncology, 2018, 14, 319-329.	2.4	5
36	Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1271-1273.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	1.6	55
38	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	2.4	6
39	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	4.4	13
40	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
41	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
42	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	7.2	83
43	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. <i>Blood</i> , 2018, 132, 125-125.	1.4	10
44	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0
45	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. <i>Blood</i> , 2018, 132, 2023-2023.	1.4	0
46	Renal failure in multiple myeloma: something new on the horizon. <i>British Journal of Haematology</i> , 2017, 176, 845-846.	2.5	3
47	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 289-295.	2.2	2
48	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	4.1	19
49	Stem Cell Transplantation in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 769-781.	1.6	2
50	Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. <i>Oncotarget</i> , 2016, 7, 77543-77557.	1.8	62
51	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	1.8	33
52	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
53	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
54	Oral ixazomib maintenance therapy in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 21-32.	2.4	6

#	ARTICLE	IF	CITATIONS
55	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
56	Carfilzomib in Combination with Bendamustine and Dexamethasone (CbD) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016, 128, 3334-3334.	1.4	5
57	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <sc>SEIFEM</sc> registry. <i>British Journal of Haematology</i> , 2015, 170, 434-439.	2.5	14
58	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
59	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	5.5	25
60	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015, 6, 17543-17558.	1.8	55
61	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , 2015, 100, 284-292.	3.5	64
62	Smoldering multiple myeloma: to treat or not to treat. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 785-790.	1.8	3
63	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015, 56, 559-567.	1.3	12
64	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
65	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1287-1298.	4.1	42
66	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1617-1629.	10.7	289
67	An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. <i>OncoTargets and Therapy</i> , 2014, 7, 1793.	2.0	43
68	Pomalidomide for the treatment of relapsed/refractory multiple myeloma: a review of biological and clinical data. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 499-510.	2.4	19
69	Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1657-1660.	1.3	5
70	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
71	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	4.1	24
72	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type 2. <i>International Journal of Cancer</i> , 2014, 134, 2534-2546.	5.1	86

#	ARTICLE	IF	CITATIONS
73	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
74	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	1.6	55
75	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
76	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	27.0	683
77	Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1399-1406.	2.0	10
78	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	1.4	126
79	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	1.4	5
80	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8515-8515.	1.6	6
81	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013, 88, 16-23.	4.1	60
82	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24
83	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 619-634.	4.1	17
84	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 3247-3258.	7.0	50
85	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 3130-3142.	7.0	86
86	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013, 122, 1376-1383.	1.4	74
87	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
88	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	1.4	17
89	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
90	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 3126-3126.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1449-1462.	3.1	18
92	Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. <i>European Journal of Haematology</i> , 2012, 89, 276-277.	2.2	14
93	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1722-1727.	1.3	43
94	Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 423-432.	0.4	41
95	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	4.4	18
96	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. <i>Cancer</i> , 2012, 118, 1574-1584.	4.1	102
97	Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. <i>Leukemia and Lymphoma</i> , 2011, 52, 776-785.	1.3	27
98	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
99	How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 779-793.	4.1	9
100	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
101	Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 1449-1456.	1.8	19
102	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	1.4	34
103	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010, 84, 223-228.	2.2	77
104	ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with <i>de novo</i> multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 474-483.	2.2	20
105	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
106	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 800-807.	1.6	166
107	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 353-360.	0.4	4
108	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet</i> , 2010, 376, 2075-2085.	13.7	770

#	ARTICLE	IF	CITATIONS
109	Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1444-14449.	1.3	3
110	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	1.6	400
111	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
112	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5001-5007.	1.6	46
113	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	2.2	21
114	Thalidomide+dexamethasone versus Interferon+alpha+dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. <i>British Journal of Haematology</i> , 2009, 144, 653-659.	2.5	37
115	New Combination Approaches for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S42-S43.	1.4	0
116	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie Tm) ETQq0 0 0 rgBT /Overlock 10 Tf 5 10, 906-922.	2.1	9
117	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. <i>Blood</i> , 2009, 114, 492-492.	1.4	14
118	Serum C-Reactive Protein at Diagnosis and Response to Therapy Is the Most Powerful Factor Predicting Outcome of Multiple Myeloma Treated with Thalidomide/Anthracycline-Based Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 294-299.	1.4	9
119	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
120	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 158-158.	1.4	25
121	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	1.4	33
122	Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality--SEIFEM-C Report. <i>Clinical Infectious Diseases</i> , 2007, 44, 1524-1525.	5.8	102
123	Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. <i>Haematologica</i> , 2007, 92, 686-689.	3.5	56
124	Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. <i>British Journal of Haematology</i> , 2007, 136, 729-735.	2.5	32
125	A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. <i>Experimental Hematology</i> , 2007, 35, 1074-1082.	0.4	7
126	Thalidomide+dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide+dexamethasone: a case-matched study in advanced multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 297-302.	2.2	30



#	ARTICLE	IF	CITATIONS
127	Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2006, 108, 2159-2164.	1.4	101
128	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. <i>Blood</i> , 2006, 108, 3951-3952.	1.4	53
129	Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2006, 14, 874-877.	2.2	4
130	Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. <i>Haematologica</i> , 2006, 91, 133-6.	3.5	63
131	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. <i>Haematologica</i> , 2006, 91, 1068-75.	3.5	650
132	Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). <i>Leukemia and Lymphoma</i> , 2005, 46, 233-238.	1.3	17
133	Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. <i>European Journal of Haematology</i> , 2005, 75, 136-145.	2.2	79
134	Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 312-317.	1.4	30
135	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. <i>European Journal of Haematology</i> , 2004, 72, 403-409.	2.2	43
136	Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. <i>European Journal of Haematology</i> , 2004, 72, 10-17.	2.2	43
137	Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates. <i>Cancer</i> , 2004, 101, 567-577.	4.1	15
138	Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).. <i>Blood</i> , 2004, 104, 4490-4490.	1.4	5
139	Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at -80°C. <i>Transfusion</i> , 2003, 43, 42-49.	1.6	35
140	High-dose daunorubicin as liposomal compound (Daunoxome®) in elderly patients with acute lymphoblastic leukemia. <i>The Hematology Journal</i> , 2003, 4, 47-53.	1.4	23
141	Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. <i>Haematologica</i> , 2003, 88, 1432-3.	3.5	11
142	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. <i>British Journal of Haematology</i> , 2002, 117, 379-386.	2.5	123
143	Acycloguanosine for the treatment of aplastic anaemia. <i>European Journal of Haematology</i> , 1991, 46, 120-121.	2.2	5